此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

JAK Signaling in Depression and Cognition in Male Football Players (JAK DC in Play)

2026年8月18日 更新者:Andrew H Miller、Emory University
This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 11 years of organized tackle football. This will be evaluated using a medication called baricitinib, which blocks one aspect of inflammation.

研究概览

地位

尚未招聘

详细说明

This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 10 years of football. This will be assessed using a medication called baricitinib that blocks one aspect of inflammation.

This study will enroll depressed adult male football players enriched for high inflammation [blood levels of C-reactive protein (CRP)], anhedonia, and cognitive dysfunction.

Qualifying participants will be asked to take the study medication once daily by mouth for 8 weeks and undergo MRI scans, provide blood and urine samples for safety or to measure biomarkers of inflammation, complete clinician-rated and self-report assessments of depressive and cognitive symptoms, and perform computer or paper-and-pencil tests of neurocognitive function. Blood and other biological samples may be stored for future research use, with the participant's consent.

研究类型

介入性

注册 (估计的)

30

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Andrew H Miller, MD
  • 电话号码:404-727-8260
  • 邮箱:amill02@emory.edu

学习地点

    • Georgia
      • Atlanta、Georgia、美国、30329
        • Emory University
      • Atlanta、Georgia、美国、30322
        • Emory Clinic, Emory University Hospital
      • Atlanta、Georgia、美国、30322
        • Emory School Of Medicine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

Inclusion Criteria:

  • willing and able to give written informed consent
  • males
  • playing tackle football for at least 11 years
  • 30-55 years of age
  • Current Diagnostic and Statistical Manual (DSM)-V major depression or Bipolar, depressed type; or DSM-V major depression or Bipolar, depressed type in partial remission as diagnosed by the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID)-V
  • score of >10 on the PHQ-9 from screening and HAM-D score ≥16 for study entry
  • off all antidepressant or other psychotropic therapy (e.g., mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks before baseline visit (8 weeks for fluoxetine) or on a stable psychotropic regimen for at least 4 weeks (and no planned changes)
  • CRP ≥3 mg/L
  • PHQ-9 anhedonia (item #1) and cognitive (item #7) scores ≥2

Exclusion Criteria:

  • current or history of past autoimmune disorder
  • history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection
  • history of any type of cancer requiring treatment with more than minor surgery
  • unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG, and laboratory testing)
  • significant hematological abnormalities at screening (ANC < 1500, Hgb<10, platelet< 100,000)
  • history of progressive multifocal leukoencephalopathy
  • history of deep venous thrombosis
  • history of cardiovascular disease (coronary artery disease, congestive heart failure, stroke - controlled hypertension is OK)
  • major surgery within 6 months before screening, or will require major surgery during the study
  • current or recent (<4 weeks before study start) viral (including COVID-19), bacterial, fungal, or parasitic infection, or any other active or recent infection
  • symptomatic herpes zoster infection at or within 12 weeks of study start
  • history of disseminated/complicated herpes zoster (for example, ophthalmic zoster or CNS involvement)
  • cirrhosis of the liver from any cause
  • Additional exclusion criteria apply

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Baricitinib
Participants will receive 1 tablet/d of 2 mg baricitinib at baseline. For participants who do not exhibit a clinical response at 4 Weeks (a 50% reduction in HAM-D scores), the dose will be increased to 4 mg/day (2 tablets/d of baricitinib), as tolerated.
Baricitinib is an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2. It reduces cytokine-mediated signaling involved in inflammation and immune activation. Baricitinib is FDA-approved for rheumatoid arthritis (RA), atopic dermatitis, and alopecia areata. It has also been authorized for the treatment of COVID-19 in hospitalized patients. Baricitinib will be dispensed every other week at the Week 2, 4, and 6 study visits. Participants who do not exhibit a clinical response (50% reduction in HAM-D scores from baseline) at Week 4 will be increased to 4 mg/day of baricitinib (2 x 2 mg tablets). A virtual follow-up visit will be conducted at Week 1 to assess safety and tolerability in all patients, and at Week 5 in patients who increase the dose.
其他名称:
  • 发光体

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Monetary Incentive Delay (MID) Task functional magnetic resonance imaging (fMRI)
大体时间:Baseline and weeks 2 and 8 post-intervention
Resting-state and task-based MID Task functional magnetic resonance imaging (fMRI). The MID Task is a specialized behavioral paradigm used during functional magnetic resonance imaging (fMRI). It isolates and measures the neural mechanisms of reward processing, specifically motivational salience, anticipation, and outcome feedback. fMRI blood oxygen level-dependent (BOLD) for resting and task-based functional connectivity: A multi-echo (ME) ep2 BOLD sequence will be optimized to provide a high signal-to-noise ratio in regions of interest that is maintained during minor incidences of head motion. Resting ME BOLD will be acquired over ~10 min, and task fMRI will involve two ~10 min scans. For resting bold, a single acquisition of phase-encoding in the opposite polarity (anterior-posterior) for distortion correction over ~30 seconds.
Baseline and weeks 2 and 8 post-intervention

次要结果测量

结果测量
措施说明
大体时间
Effort-Expenditure for Rewards Task (EEFRT)
大体时间:Baseline and weeks 2, 4 and 8 post-intervention

The EEfRT is a widely used, multi-trial task measuring motivation for rewards as an assessment of anhedonia, as anhedonia is specifically associated with decreased motivation for rewards.

Participants are given an opportunity to choose between two different task difficulty levels in order to obtain monetary rewards by repeated manual button presses within a short time. Button presses raise a virtual ''bar'' viewed onscreen. If they raise the bar to the ''top'' within the prescribed time, they are eligible to win the allotted money. Each trial presents the subject with a choice between two levels of task difficulty, a 'hard task' and an 'easy task,' and 3 probabilities of winning. Subjects participate in the task for 20 minutes, and the first 50 trials are analyzed by calculating the proportion of hard-task choices across each level of probability. Lower proportions of hard task choices indicate decreased motivation.

Baseline and weeks 2, 4 and 8 post-intervention
Finger Tapping Test (FTT)
大体时间:Baseline and weeks 2, 4 and 8 post-intervention

The Finger Tapping Test (FTT) is a simple neuropsychological assessment that measures fine motor speed, coordination, and nervous system health. This task uses a specially adapted tapper that the subject is asked to tap as fast as possible using the index finger. The subject is given 5 consecutive 10-second trials for both the preferred and non-preferred hands. The finger tapping score is the mean of the 5 trials and is computed for each hand.

Normal/Average: 45-60 taps. Mild Slowing / Potential Impairment: 30-45 taps. Significant Motor Impairment / Fatigue: Fewer than 30 taps

Baseline and weeks 2, 4 and 8 post-intervention
Trail-Making Test (TMT)
大体时间:Baseline and weeks 2, 4 and 8 after baricitinib started
The Trail-Making Test (TMT) is a common neuropsychological assessment measuring processing speed, visual attention, and task-switching ability. The test is typically administered using a paper-and-pencil format (or digital equivalent) and has two primary sections: Part A: Patients connect 25 randomly distributed circles containing numbers in ascending order (1, 2, 3...) as quickly as possible. This measures baseline processing speed, motor speed, and visual scanning. Part B: Patients connect 25 circles containing both numbers and letters, strictly alternating between them in ascending order (1-A-2-B-3-C...). This places a much higher cognitive demand on mental flexibility, set-shifting, and working memory. Evaluators record the total time (in seconds) taken to complete each part. Longer times generally indicate poorer cognitive function.
Baseline and weeks 2, 4 and 8 after baricitinib started
Anhedonia Subscale of the Inventory of Depressive Symptoms-Self Reported (IDSSR)
大体时间:Baseline and weeks 2, 4, 6, and 8 post-intervention
Anhedonia is assessed with a 3-item subscale of the Inventory of Depressive Symptomatology Self-Report (IDS-SR). Each of the three items is rated on a 4-point severity scale from 0 to 3, where 0 indicates no impairment, and 3 indicates maximum severity. Scores range from 0 to 9, with higher scores reflecting a greater severity of anhedonia, meaning a stronger loss of interest, motivation, and ability to experience pleasure.
Baseline and weeks 2, 4, 6, and 8 post-intervention
Behavior Rating Inventory of Executive Function, Second Edition (BRIEF2A)
大体时间:Baseline and weeks 2 and 8 post-intervention

BRIEF2A is a standardized rating scale that allows adults and knowledgeable informants (caregivers, adult children, partners/spouses) to rate executive function or self-regulation in that adult's day-to-day setting. Scoring relies on T-scores (Mean = 50, Standard Deviation = 10).

< 60 T-score: Within Normal Limits. 60 - 64 T-score: Subclinical difficulties; subtle but generally manageable challenges.

65 - 69 T-score: Mildly elevated; noticeable executive function deficits. 70 - 74 T-score: Moderately elevated; significant executive dysfunction affecting daily life.

>= 75 T-score: Highly elevated; severe impairment.

Baseline and weeks 2 and 8 post-intervention
Snaith-Hamilton Pleasure Scale-Clinician (SHAPS-C)
大体时间:Baseline and weeks 2, 4, 5, 6, and 8 after baricitinib started
The Snaith-Hamilton Pleasure Scale-Clinician (SHAPS-C) is a 14-item validated clinician-administered assessment tool used to measure hedonic capacity and evaluate anhedonia (the inability to experience pleasure). The clinician asks the patient about their expected or actual ability to feel pleasure over the past few days, translating the standard self-report questions into a guided clinical interview. Responses are typically evaluated using a 4-point Likert scale (Strongly Disagree, Disagree, Agree, Strongly Agree). Total scores range from 0 to 14, with higher scores indicating greater difficulty experiencing pleasure or a higher level of anhedonia.
Baseline and weeks 2, 4, 5, 6, and 8 after baricitinib started
Hamilton Depression (HAM-D) Rating Scale
大体时间:Baseline and weeks 2, 4, 5, 6, and 8 post-intervention

Hamilton Depression (HAM-D) Rating Scale is the most widely used clinician-administered depression assessment scale. It evaluates symptoms such as mood, guilt, insomnia, anxiety, and weight loss over the previous week.

Scores are tallied to estimate the severity of the depression, although context and clinical judgment are always required. Maximum score is 52 0 to 7: Normal/Remission 8 to 16: Mild Depression 17 to 23: Moderate Depression 24 or higher: Severe Depression

Baseline and weeks 2, 4, 5, 6, and 8 post-intervention
Columbia Suicide Severity Rating Scale (CSSR)
大体时间:Baseline and weeks 2, 4, 5, 6, and 8 post-intervention

The Columbia-Suicide Severity Rating Scale (C-SSRS) evaluates both suicidal ideation and suicidal behavior.

Minimum 0 (no ideation) to Max: 5 (active suicidal ideation with a specific plan and intent).

Meaning of Scores:0: No suicidal ideation reported.

  1. (Wish to be Dead): Endorses thoughts about a wish to be dead or not alive.
  2. (Non-Specific Thoughts): General, non-specific thoughts of wanting to end life, without methods or plans.
  3. (Method, No Intent/Plan): Thoughts of suicide with a specific method in mind, but no intent or actual plan to act.
  4. (Some Intent, No Plan): Thoughts of suicide and some intent to act, but without fully mapped-out details.
  5. (Specific Plan and Intent): Fully or partially worked-out details of a suicide plan with intent to carry it out.
Baseline and weeks 2, 4, 5, 6, and 8 post-intervention
Phosphorylated Signal Transducer and Activator of Transcription 3 (pSTAT3)
大体时间:Baseline and weeks 2 and 8 post-intervention
Intracellular pSTAT3 in peripheral blood immune cells will be assessed by flow cytometric methods.
Baseline and weeks 2 and 8 post-intervention
Inflammatory cytokines (IL-1, IL-6, TNF)
大体时间:Baseline and weeks 2 and 8 post-intervention
IL-1, IL-6, TNF and their soluble receptors will be analyzed by multiplex bead-based assays, previously validated against individual ELISA.
Baseline and weeks 2 and 8 post-intervention
High-sensitivity (hs) CRP
大体时间:Baseline and weeks 2 and 8 post-intervention
High-sensitivity (hs) CRP will be assayed using an immunoturbidometric assay with a Beckman AU480 chemistry analyzer and Ultra WR CRP kit (Sekisui Diagnostics).
Baseline and weeks 2 and 8 post-intervention

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Andrew H Miller, MD、Emory University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2027年10月1日

研究完成 (估计的)

2027年10月1日

研究注册日期

首次提交

2026年5月20日

首先提交符合 QC 标准的

2026年5月20日

首次发布 (实际的)

2026年5月27日

研究记录更新

最后更新发布 (实际的)

2026年8月20日

上次提交的符合 QC 标准的更新

2026年8月18日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅